A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Inclusion Criteria:

• Patients with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA)pustulation sub-score of 0 or 1 and a known and documented history of GeneralizedPustular Psoriasis (GPP) (per European Rare And Severe Psoriasis Expert Network -ERASPEN - criteria), regardless of Interleukin 36 Receptor Antagonist (IL-36RN) genemutation status or Patients with a GPP flare and a known and documented history ofGPP (per ERASPEN criteria) regardless of IL-36RN gene mutation status.

• Patients must have a history of frequent GPP flares in the past

• Male or female patients, aged ≥18 years (if local legislation for age of consentdiffers, then local legislation will be followed) at screening

• Signed and dated written informed consent prior to admission to the trial inaccordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to start of any screening procedures

• Women of childbearing potential (WOCBP) must be ready and able to use highlyeffective methods of birth control per ICH M3 (R2) that result in a low failure rateof less than 1% per year when used consistently and correctly

Exclusion Criteria:

• Drug-triggered Acute Generalized Exanthematous Pustulosis (AGEP)

• Patients with primary plaque psoriasis vulgaris without presence of pustules or withpustules that are restricted to psoriatic plaques

• Patients with primary erythrodermic psoriasis vulgaris

• Patients with SAPHO (Synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome

• Immediate life-threatening flare of GPP or requiring intensive care treatment,according to the investigator's judgement. Life-threatening complications mainlyinclude, but are not limited to, cardiovascular/cytokine driven shock, pulmonarydistress syndrome, or acute renal failure

• Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold upper limitnormal (ULN) elevation in Aspartate Aminotransferase (AST) or AlanineAminotransferase (ALT) or alkaline phosphatase, or >2-fold ULN elevation in totalbilirubin

• Presence of acute demyelinating neuropathy

• Treatment with any drug considered likely to interfere with the safe conduct of thetrial, as assessed by the investigator

• Further exclusion criteria apply.